Kaiser Permanente offers free video physician visits

| | Health Exec | Precision Medicine

Kaiser Permanente is betting on mobile health and telehealth to reduce unnecessary and costly visits to urgent care centers and hospitals.

The company recently implemented a new program, HouseCalls, that provides free, 20-minute physican appointments to patients in the areas of Washington, D.C., Virginia and Maryland.

“Our ultimate goal is to 100 percent satisfy every patient we come into contact with. They love the convenience of not having to leave their house in the middle of the night or with a painful condition that might make it difficult to leave their home,” said Jody Crane, MD, MBA, associate medical director at the Mid-Atlantic Permanente Medical Group in an interview with the Washington Post. “We will ultimately reduce our insurance premiums and we’ll be able to attract more patients because we’re providing this quality service at a price that can’t be beat.”

Read the full story below:

Innovators: At Kaiser Permanente, technology brings the doctor’s office to your…

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.